ANI Pharmaceuticals vs BeiGene
ANI Pharmaceuticals vs BeiGene, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: ANI Pharmaceuticals is on 49/100 and BeiGene on 64/100.
Where each one leads
ANI Pharmaceuticals
- funding raised: $671M against $358M
BeiGene
- our overall score: 64/100 against 49/100
- agent readiness: 50/100 against 31/100
- domain rating: 68/100 against 56/100
At a glance
| Measure | ANI Pharmaceuticals | BeiGene |
|---|---|---|
| What it is | Diversified biopharmaceutical company focused on rare diseases, generics, and established brands. | A global oncology company developing and commercializing innovative cancer treatments. |
| Category | Biotech, Pharmaceuticals, Rare Disease, Generics | Biotech, MedTech, HealthTech, Genomics |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 1996 | 2010 |
| Headquarters | Baudette, United States | Cambridge, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | ANI Pharmaceuticals | BeiGene |
|---|---|---|
| Employees | 707 | Not published |
| Headcount growthLast 12 months | +95.8% | Not published |
| Open roles | Not published | 100 |
| Total funding | $671M | $358M |
| Latest round | Acquisition | Secondary Offering |
| Valuation | Not published | $15B |
| LinkedIn followers | 31,660 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | ANI Pharmaceuticals | BeiGene |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 49/100 | 64/100 |
| Traction | 60/100 | 40/100 |
| Team | 10/100 | 30/100 |
| Search visibility | 23/100 | 17/100 |
| Quality | 58/100 | 88/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (31/100) | D (50/100) |
| Domain ratingLink authority, 0-100 | 56/100 | 68/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | ANI Pharmaceuticals | BeiGene |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Jquery, Bootstrap | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Google Analytics 4 | Not detected |
ANI Pharmaceuticals vs BeiGene: common questions
Which is better, ANI Pharmaceuticals or BeiGene?
On our 0-100 score BeiGene rates higher (64/100 against 49/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do ANI Pharmaceuticals and BeiGene compare on the numbers?
ANI Pharmaceuticals leads on funding raised ($671M against $358M). BeiGene leads on our overall score (64/100 against 49/100), agent readiness (50/100 against 31/100), domain rating (68/100 against 56/100).
Read the full ANI Pharmaceuticals review and pricing or the BeiGene review and pricing. You can also browse other ANI Pharmaceuticals alternatives we track.